Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 275 of 994 entries
View as:

Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy

Phase: N/A Priority: Normal
NCT ID: NCT04772313 Org: User:
Start: 03/08/21 End: 04/24/23 Due: 04/24/24

Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)

Phase: N/A Priority: Normal
NCT ID: NCT00117143 Org: User:
Start: 12/02/02 End: 07/19/04 Due: 07/19/05

Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00091806 Org: User:
Start: 08/31/04 End: 10/31/06 Due: 10/31/07

A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT06224192 Org: User:
Start: 04/02/24 End: 03/15/26 Due: 03/15/27

A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders

Phase: N/A Priority: Normal
NCT ID: NCT02246218 Org: User:
Start: 12/31/14 End: 07/17/17 Due: 07/17/18

AMG 319 Lymphoid Malignancy FIH

Phase: N/A Priority: Normal
NCT ID: NCT01300026 Org: User:
Start: 04/30/11 End: 12/31/16 Due: 12/31/17

Observational Study That Will Collect Information on Patients With Urea Cycle Disorders (UCDs)

Phase: N/A Priority: Normal
NCT ID: NCT01948427 Org: User:
Start: 09/25/13 End: 02/24/20 Due: 02/24/21

A Study of TEPEZZA Subcutaneous Administration in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT06563856 Org: User:
Start: 09/22/20 End: 05/27/21 Due: 05/27/22

Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01832727 Org: User:
Start: 07/02/13 End: 06/25/19 Due: 06/25/20

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Phase: N/A Priority: Normal
NCT ID: NCT05325866 Org: User:
Start: 09/23/22 End: 09/30/27 Due: 09/30/28

A Study to Evaluate the Impact of Acid-reducing Agents on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05599828 Org: User:
Start: 07/17/20 End: 09/13/20 Due: 09/13/21

A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00124111 Org: User:
Start: - End: - Due: -

A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease

Phase: N/A Priority: Normal
NCT ID: NCT06248619 Org: User:
Start: 07/05/24 End: 09/02/26 Due: 09/02/27

A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease

Phase: N/A Priority: Normal
NCT ID: NCT04540497 Org: User:
Start: 12/04/20 End: 10/31/28 Due: 10/31/29

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

Phase: N/A Priority: Normal
NCT ID: NCT06072482 Org: User:
Start: 02/07/24 End: 12/31/36 Due: 12/31/37

A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)

Phase: N/A Priority: Normal
NCT ID: NCT02103283 Org: User:
Start: 10/31/14 End: 08/31/16 Due: 08/31/17

A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma

Phase: N/A Priority: Normal
NCT ID: NCT06637371 Org: User:
Start: 10/16/24 End: 10/25/26 Due: 10/25/27

A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

Phase: N/A Priority: Normal
NCT ID: NCT06104124 Org: User:
Start: 01/24/24 End: 08/03/26 Due: 08/03/27

A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

Phase: N/A Priority: Normal
NCT ID: NCT06376045 Org: User:
Start: 05/24/24 End: 10/02/26 Due: 10/02/27

Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder

Phase: N/A Priority: Normal
NCT ID: NCT05549258 Org: User:
Start: 07/03/23 End: 04/13/27 Due: 04/13/28

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Phase: N/A Priority: Normal
NCT ID: NCT05920356 Org: User:
Start: 11/16/23 End: 06/30/31 Due: 06/30/32

ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism

Phase: N/A Priority: Normal
NCT ID: NCT00135304 Org: User:
Start: 08/31/05 End: 12/31/06 Due: 12/31/07

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT04994717 Org: User:
Start: 11/02/21 End: 09/30/31 Due: 09/30/32

Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06555796 Org: User:
Start: 09/23/24 End: 06/21/29 Due: 06/21/30

Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI

Phase: N/A Priority: Normal
NCT ID: NCT02352753 Org: User:
Start: 06/24/15 End: 03/26/22 Due: 03/26/23